


Please type a plus sign (+) in this box



RECEIVED



Approved for use through 9/30/00. OMB 0651-0051
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	TECH CENTER 1600/2900
	Filing Date	10/15/01
	First Named Inventor	Bonny
	Group Art Unit	1645
	Examiner Name	Not Yet assigned
	Attorney Docket Number	20349-512 (OTT-12)

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
PP	B1	CA	2,094,658	Allelix Biopharmaceuticals, Inc.	04/22/93		
PP	B2	WO	99/07414	Institut Pasteur	02/18/99		x
PP	B3	WO	01/64738	Diatos S.A.	09/07/01		x

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
PP	C1	Anderson (1989). <i>Clin. Immun. and Immunopathol.</i> <u>53</u> : S63-S71.
	C2	Ammendrup, et al. (2000). <i>Diabetes</i> <u>49</u> : 1468-1476.
	C3	Bleich, et al. (1999). <i>J. Clin. Invest.</i> <u>103</u> (10): 1431-1436.
	C4	Bonner-Weir (1994) <i>Recent Prog. Hormone Res.</i> <u>49</u> : 91-104.
	C5	Bonny, et al. (2001). <i>Diabetes</i> <u>50</u> : 77-82.
	C6	Breeman, et al. (1999). <i>Int. J. Cancer</i> <u>81</u> : 658-665.
	C7	Brugidou, et al. (1995). <i>Biochem. Biophys. Res. Commun.</i> <u>214</u> (2): 685-693.
	C8	Burns, et al. (1998) <i>J. Biol. Chem.</i> <u>273</u> (20): 12203-12209.
	C9	Chen, et al. (2000). <i>Diabetes</i> <u>49</u> : 562-570.
	C10	Dupraz, et al. (1999). <i>Gene Therapy</i> <u>6</u> : 1160-1169.
	C11	Efrat, et al. (1988). <i>Proc. Natl. Acad. Sci. USA</i> <u>85</u> : 9037-9041.
	C12	Flodstrom, et al. (1999). <i>Diabetes</i> <u>48</u> : 706-713.
	C13	Giannoukakis, et al. (1999). <i>Diabetes</i> <u>48</u> : 1730-1736.
	C14	Gibbs (2000). <i>Science</i> <u>287</u> : 1969-1973.
	C15	Gibbs and Oliff (1994). <i>Cell</i> <u>79</u> : 193-198.
	C16	Hofland, et al. (1999). <i>Proc. Assoc. Am. Physicians</i> <u>111</u> (1): 63-69.
	C17	Ivanenkov, et al. (1999). <i>Biochem. Biophys. Acta</i> <u>1448</u> : 463-472.
	C18	Ivanenkov, et al. (1999). <i>Biochem. Biophys. Acta</i> <u>1448</u> : 450-462.
	C19	Cabibbo, et al. (1995). <i>Gene</i> <u>167</u> : 41-47.
	C20	Iwahashi, et al. (1996). <i>Diabetologia</i> <u>39</u> : 530-536.
	C21	Iwahashi, et al. (1998). <i>Cytokines, Cell. Mol. Ther.</i> <u>4</u> : 45-51.

RECEIVED
APR 08 2002



OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
PP	C22	de Jong, et al. (1999). <i>J. Nucl. Med.</i> <u>40</u> : 2081-2087.
	C23	Kato and Sugiyama (1997). <i>Critical Rev. Thera. Drug Carr. Systems</i> <u>14</u> (3): 287-331.
	C24	Kim, et al. (2000). <i>Anticancer Res.</i> <u>20</u> : 439-444.
	C25	Larsen, et al. (1998). <i>J. Biol. Chem.</i> <u>273</u> (24): 15294-15300.
	C26	Lin, et al. (1995). <i>J. Biol. Chem.</i> <u>270</u> (24): 14255-14258.
	C27	Lund, et al. (1990). <i>J. Biol. Chem.</i> <u>265</u> (25): 15713-15723.
	C28	Mahato, et al. (1997). <i>Critical Rev. Thera. Drug Carr. Systems</i> <u>14</u> (2): 133-172.
	C29	Mahato, et al. (1997). <i>J. Drug Targeting</i> <u>4</u> (6): 337-357.
	C30	Mandrup-Poulsen (1996). <i>Diabetologia</i> <u>39</u> : 1005-1029.
	C31	Mandrup-Poulsen (1998). <i>BMJ</i> <u>316</u> : 1221-1225.
	C32	Mukherjee, et al. (1997). <i>Physiol. Rev.</i> <u>77</u> (3): 759-803.
	C33	Negri, et al. (2000). <i>Genomics</i> <u>64</u> : 324-330.
	C34	Nerup, et al. (1988). <i>Diabetes Care</i> <u>11</u> (supp. 1): 16-23.
	C35	Oehlke, et al. (1998). <i>Biochem. Biophys. Acta</i> <u>1414</u> : 127-139.
	C36	Offord, et al. (1997). <i>Meth. Enzymol.</i> <u>287</u> : 348-369.
	C37	Pasqualini and Ruoslahti (1996). <i>Mol. Psychiatry</i> <u>1</u> : 423.
	C38	Peralta, et al. (1990). <i>Endocrinol.</i> <u>127</u> (2): 595-603.
	C39	Rabinovitch, et al. (1999). <i>Diabetes</i> <u>48</u> : 1223-1229.
	C40	Renschler, et al (1994). <i>Proc. Natl. Acad. Sci. USA</i> <u>91</u> : 3623-3627.
	C41	Roitt (1991). <i>Essential Immunology</i> . Chapter 4: 65-83.
	C42	Rose and Vizzavona (1999) <i>J. Am. Chem. Soc.</i> <u>121</u> : 7034-7038.
	C43	Rouquet, et al. (1996). <i>Curr. Biol.</i> <u>6</u> (9): 1192-1195.
	C44	Scharfmann and Czernichow (1996). <i>Diabetes and Metabolism</i> <u>22</u> : 223-228.
	C45	Schwarze, et al. (1999). <i>Science</i> <u>285</u> : 1569-1572.
	C46	Scott and Smith (1990). <i>Science</i> <u>249</u> : 386-390.
	C47	Sjoholm (1998). <i>Cell Death Diff.</i> <u>5</u> : 461-468.
	C48	Smith and Jarett (1988). <i>Laboratory Invest.</i> <u>58</u> (6): 613-629.
	C49	Smith and Scott (1993). <i>Meth. Enzymol.</i> <u>217</u> : 228-257.
	C50	Stephens, et al. (1997). <i>J. Autoimmunity</i> <u>10</u> : 293-298.
	C51	Stephens, et al. (1999). <i>Endocrinol.</i> <u>140</u> (7): 3219-3227.
	C52	Suzuki, et al. (2002). <i>J. Biol Chem.</i> <u>277</u> (4): 2437-2443.
	C53	Terskikh, et al. (1997). <i>Proc. Natl. Acad. Sci. USA</i> <u>94</u> : 1663-1668.
	C54	Thorens (1992). <i>Proc. Natl. Acad. Sci. USA</i> <u>89</u> : 8641-8645.
	C55	Torgerson, et al. (1998). <i>J. Immunology</i> <u>161</u> : 6084-6092.
	C56	Ulbrich, et al. (2000). <i>J. Controlled Rel.</i> <u>64</u> : 63-79.
	C57	Usami, et al. (1998). <i>Biochem Pharmacol.</i> <u>55</u> : 185-191.
	C58	Wang, et al. (1999). <i>Endocrinol.</i> <u>140</u> (3): 1200-1204.
	C59	Welsh, et al. (1999). <i>Mol. Med.</i> <u>5</u> : 169-180.
	C60	Widmann, et al. (1995). <i>Biochem J.</i> <u>315</u> : 203-214.
	C61	Yamada, et al. (1999). <i>Diabetes</i> <u>48</u> : 478-483.
	C62	Yoon, et al. (1999). <i>Science</i> <u>284</u> : 1183-1187.
	C63	York, et al. (1999). <i>J. Biol Chem.</i> <u>274</u> (2): 1164-1171.
	C64	Zacher, et al. (1980). <i>Gene</i> <u>9</u> : 127-140.

RECEIVED

FEB 20 2002

TECH CENTER 1600/2900

RECEIVED

APR 18 2002

TECH CENTER 1600/2900



RECEIVED Page 3 of 3

APR 08 2002

OTHER PRIOR ART AND PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
P	C65	Zeng, et al. (1996). <i>J. Peptide Sci.</i> 2: 66-72.
	C66	Zwick, et al. (1998). <i>Curr. Opin. Biotech.</i> 9: 427-436.
	C67	Pasquallini and Ruoslahti (1996). <i>Nature</i> 380: 364-366.
	C68	Sela and Zisman (1997). <i>FASEB J.</i> 11: 449-456.
	C69	Volz, et al. (1995). <i>FEBS Letters</i> 373: 23-29.
	C70	Yamato, et al. (1997). <i>Horm. Metab. Res.</i> 29: 56-59.
	C71	Bonny, et al. (2000). <i>J. Biol. Chem.</i> 275(22): 16466-16472.
	C72	Hoorens, et al. (1996). <i>J. Clin. Invest.</i> 98(7): 1568-1574.
	C73	Bonny, et al. (1998). <i>J. Biol. Chem.</i> 273(4): 1843-1846.
	C74	Sela and Zisman (1997). <i>FASEB J.</i> 11: 449-456.
	C75	Gotoh, et al. (1987). <i>Transplantation</i> 43(5): 725-730.
	C76	Carithers and Lerner (1996). <i>Chem. Biol.</i> 3: 537-542.
	C77	Damke (1996). <i>FEBS Letters</i> 389: 48-51.
	C78	Hawiger (1999). <i>Current Opinion Chem. Biol.</i> 3: 89-94.
	C79	Avrameas, et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> 95: 5601-5606.
	C80	Rothbard, et al. (2000). <i>Nature Med.</i> 6(11): 1253-1257.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	P. Ponnaluri	Date Considered	9/28/03
--------------------	--------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1628855v1



Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/977,831
	Filing Date	10/15/01
	First Named Inventor	Bonny
	Group Art Unit	1645/1639
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	20349-512

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
PP	B4	WO 98/51325	Cytogen Corporation WIPO	11/19/1998		
PP	B5	WO 98/51825	Elan Corporation WIPO	11/19/1998		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
PP	C81	Partial International Search Report for PCT/IB01/02423. Mailed on July 2, 2002.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	P. Ponnaluri	Date Considered	9/28/03
---------------------------	--------------	------------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

RECEIVED
JUL 31 2002
TECH CENTER 1600/2900